ZBIO · Zenas BioPharma, Inc.

The thesis

Zenas BioPharma's case still turns on the SunStone Phase 2 lupus trial of obexelimab, and the primary-endpoint result due in the fourth quarter of 2026 settles it. A success would take the drug beyond immunoglobulin G4-related disease (IgG4-RD), where the Food and Drug Administration (FDA) has set a 27 May 2027 target action date.

The narrative is maturing: the IgG4-RD approval path has been well known since the FDA accepted the application in August 2026, and the 27 October R&D event and 5 November report repeated the timetable without a new randomized readout. The adjusted daily close was $25.93 on 5 November 2026, which is 39.9% below the $43.17 52-week high and 18.9% lower than three months earlier. The third-quarter report showed a wider loss, more share issuance and $647.1 million of cash, cash equivalents and investments at 30 September.

Bullish and bearish views on Zenas BioPharma, Inc.

The bull case on Zenas BioPharma, Inc. (ZBIO), in brief: The FDA date and INDIGO result stand. The bear case: The quarterly loss widened sharply.

Bull case

• The FDA date and INDIGO result stand. Zenas reported on 2 June 2026 that INDIGO cut IgG4-RD flare risk by 56% versus placebo (hazard ratio 0.44) and met all four key secondary endpoints. The 5 November release repeats the 27 May 2027 action date and says the European Medicines Agency validated the marketing application.
• Lupus timing was repeated in November. The 5 November release expects SunStone topline results, including a biomarker subset, in the fourth quarter of 2026. MarketBeat's 30 October account of the R&D event gave the same timing.
• On 5 November, Zenas kept its guidance for funding through at least the second quarter of 2029.
• Analyst targets sit above the shares. Investing.com listed a target range of $32 to $59 on 20 October 2026, including Guggenheim at $55 and HC Wainwright at $44. MarketBeat listed Citigroup at $48 and Wedbush at $45 the same day, against the $25.93 close on 5 November.
• ZB021 offers a second near-term readout. Zenas expects Phase 1 data for the oral IL-17AA/AF inhibitor in the fourth quarter of 2026, per the 5 November release. Proof-of-concept data are guided for 2027.

Bear case

• The quarterly loss widened sharply. Zenas reported a third-quarter 2026 net loss of $108.9 million, against $51.5 million a year earlier. The $(1.65) loss per share missed the $(1.33) estimate in a 5 November earnings headline, with $27.5 million of acquired research milestones in the quarter.
• Revenue remains milestone income. The $10.0 million of third-quarter revenue came from a Bristol-Myers Squibb development milestone, according to the 5 November release. Zenas has no approved product yet.
• Share supply keeps growing. The third-quarter 10-Q shows 1,818,181 shares sold through the at-the-market program for about $48.5 million net, plus 2,000,000 shares issued to InnoCare as a milestone payment. Shares outstanding were 67,817,793 on 30 October 2026, and resale of up to 7,000,000 InnoCare shares has been registered since 11 September.
• Morgan Stanley's odds are more restrained. Morgan Stanley's Equalweight rating and $32 target, reported 20 October 2026, mark the low end of the analyst range. The firm assigns the lupus readout a 55% probability of success and notes that Amgen's Uplizna has higher efficacy in cross-trial comparisons and less frequent dosing.
• The lupus result can break the expansion case. A SunStone miss would leave the valuation resting mainly on IgG4-RD. Zenas guides only to "fourth quarter" as of 5 November 2026, after earlier guiding to mid-2026 in August 2025.
• Runway guidance depends on approval. The 5 November guidance assumes a $75 million Royalty Pharma milestone and a $75 million Pharmakon debt draw, both tied to FDA approval. Balance-sheet obligations at 30 September included $223.2 million of convertible notes, a $76.1 million term loan and a $99.2 million royalty obligation.
• The finance chief role remains open. The chief financial officer moved to a strategic-adviser role on 30 September 2026. The 5 November release names Jerald Korn as Chief Legal and Strategy Officer and announces no new finance chief.

Price setup

The adjusted daily close was $25.93 on 5 November 2026, the day of the third-quarter report. That compares with $28.23 on 22 October and a 52-week high of $43.17. The 14-day relative strength index, a momentum gauge, was 54.8, a neutral reading.

Prices sit between the $43.17 high and the $24 invalidation level, with the April swing low near $21 beneath it. A weekly close below $24 would undo the summer rebound.

Crowding evidence points to supply more than to chasing. The shares are 39.9% below their high, and the observable pressure is at-the-market issuance plus registered InnoCare resale capacity. Filings reviewed for this note show no completed InnoCare sale. The next earnings report is no longer close, so the nearest event risk is the SunStone readout itself.

Catalysts, next 30 days

• No confirmed date inside 30 days. Zenas has not announced a specific date for its guided fourth-quarter readouts, and either could arrive within the next 30 days.
• ~31 December 2026, est.: SunStone Phase 2 topline in lupus. The 5 November release guides to the fourth quarter, including a biomarker subset. This is the event the case turns on.
• ~31 December 2026, est.: ZB021 Phase 1 data. The 5 November release guides to the fourth quarter. MarketBeat's 30 October account says the study will report pharmacokinetic, safety and tolerability results, and that the first proof-of-concept indication is undecided, with the focus on rheumatology.
• 27 May 2027: FDA target action date for obexelimab in IgG4-RD. It also determines whether the $75 million milestone and $75 million debt draw in the runway guidance become available.

What would change the view

A SunStone primary-endpoint miss would break the expansion case. A win confined to the biomarker subset would leave a narrower case than a win in the overall population. Either a slip of the readout past 31 December 2026 or a change to the 27 May 2027 FDA action date would undercut the timetable the thesis relies on.

A later report that moves funding guidance earlier than the second quarter of 2029 would weaken the cash argument. A filing showing large InnoCare disposals would confirm the supply concern. A weekly close below $24 would also end the case, because it would undo the summer rebound and point toward the April swing low near $21.

What it trades with

The next major move depends on company-specific trial results, so sector moves are likely to matter less than SunStone if the readout lands this quarter. A broad biotech rally without a primary-endpoint success would not change that view.

The direct competitive comparison is Amgen's Uplizna, which Morgan Stanley weighed against obexelimab on 20 October 2026 on dosing route, insurance coverage and cross-trial efficacy. Zenas is also tied to InnoCare through ZB021, orelabrutinib and share issuance, and to Royalty Pharma and Pharmakon through approval-linked funding.